ALLTogether-1
ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

The treatment protocol collects the experience of previously successful treatment of children and young adults, with acute lymphoblastic leukaemia (ALL) from a number of well-renowned study groups int [...]

Area: Haematological cancer

Phase: Phase III

Status: Active (recruiting)

ANIMATE
A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy

Single-arm, open label, multicentre phase II trial.

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

AVENuE
Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study

AVENuE is a non-randomised, single arm Phase II trial investigating how patients with newly diagnosed, untreated advanced classical Hodgkin lymphoma respond to treatment with the monocolonal antibody, [...]

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

BCT
PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA

BCT is a non-randomised, single arm, multicentre, phase II trial of bortezomib consolidation after high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for patients with multiple my [...]

Area: Haematological cancer

Phase: Phase II

Status: Archived

CARAMEL
Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients with Previously Untreated Mantle Cell Lymphoma

CARAMEL is a phase II, multicentre, single arm, open label pilot study to assess the safety and efficacy of acalabrutinib in combination with rituxmab in combination with rituximab for previously untr [...]

Area: Haematological cancer

Phase: Phase II

Status: In set-up (funded)

Cardamon
Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT

Cardamon is a randomised (1:1), multicentre, phase II trial of carfilzomib, cyclophosphamide and dexamethasone (CarCyDex) as induction in untreated patients with symptomatic multiple myeloma who are c [...]

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

CiproPAL
CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia): A randomised trial to assess the use of ciprofloxacin prophylaxis to prevent bacterial infection in children treated on the induction phase of the ALLTogether1 treatment protocol.

Multi-centre, randomised open-label trial

Area: Haematological cancer

Phase: Phase III

Status: Active (recruiting)

CORAL
Randomised study of ICE + Rituximab (R-ICE) versus DHAP Rituximab (R-DHAP) in previously treated patients with CD20 positive diffuse large B-cell Non-Hodgkins lymphoma, eligible for high dose chemotherapy followed by randomised maintenance treatment with Rituximab

CORAL is a multicentre, phase III open-label, randomized trial evaluating the efficacy of R-ICE compared to R-DHAP with previously treated diffuse large B-cell lymphoma, followed by high-dose chemothe [...]

Area: Haematological cancer

Phase: Phase III

Status: Closed

EMN12/HO129 pPCL
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients. A European Intergroup Trial of the European Myeloma Network (EMN)

Phase 2, prospective, multicenter trial.

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

EsPhALL2017
International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Eligible patients will be registered into the study during their induction chemotherapy, once their Philadelphia chromosome status has been confirmed.All patients will have EsPhALL induction chemother [...]

Area: Haematological cancer

Phase: Phase III

Status: Active (recruiting)

FoRT
Follicular Radiotherapy Trial - A Phase III multi-centre randomised controlled trial of low dose radiotherapy for follicular lymphoma and marginal zone lymphoma.

Area: Haematological cancer

Phase: Phase III

Status: Archived

HOVON 127 Burkitt Lymphoma
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

HOVON 127 BL is a randomized, open-label, prospective, multicentre phase III study. All eligible patients will be randomized to receive either R-CODOX-M/R-IVAC or DA-EPOCH-R.

Area: Haematological cancer

Phase: Phase III

Status: Closed

IDRIS
Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma

IDRIS is a multicentre randomised phase III study investigating whether a combination of lenalidomide and dexamethasone can delay or prevent disease progression in patients with newly-diagnosed solita [...]

Area: Haematological cancer

Phase: Phase III

Status: In follow-up (non-recruiting)

INCA
A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin (INO) plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of patients with Diffuse Large B Cell Lymphoma (DLBCL) who

INCA is a multicentre, randomised, phase II trial comparing IO-R-CVP with Gem-R-CVP in the first line treatment of patients with DLBCL who are not fit for anthracycline-containing chemotherapy.

Area: Haematological cancer

Phase: Phase II

Status: Closed

MCL MiniAllo
Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma

MCL MiniAllo is a single arm, non−randomised phase II study investigating the use of reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma in first remission.

Area: Haematological cancer

Phase: Phase II

Status: Closed

PADIMAC
Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT.

PADIMAC is non-randomised, single arm, multicentre phase II trial evaluating the safety of multiple myeloma patients that have achieved a Complete Response (CR) or Very Good Partial Response (VGPR) po [...]

Area: Haematological cancer

Phase: Phase II

Status: Closed

PAIReD
Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma

PAIReD is a multicentre phase II single-arm trial of BEAM-Campath conditioned reduced intensity stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma.

Area: Haematological cancer

Phase: Phase II

Status: Closed

PembroWM
A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström’s macroglobulinaemia

A phase II, non-randomised, single arm, open-label trial.

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

PLACARD
Phase Ib/II trial of Histone Deacetylase Inhibitor CXD101 in combination with Programmed Cell Death Protein-1 Inhibitor Pembrolizumab for relapsed or refractory Diffuse Large B-cell Lymphoma

Phase Ib/II non randomised multi centre study

Area: Haematological cancer

Phase: Phase I/II

Status: Closed

PORT
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma

PORT is a multicentre, single arm, phase II trial of pembrolizumab in combination with radiotherapy for patients with relapsed/refractory CTCL.

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

PRIMA
A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy

PRIMA is an open label, international, multicentre, randomiszed study with two treatment phases. During the first phase, patients will be evaluated for response to different induction regimens. In the [...]

Area: Haematological cancer

Phase: Phase III

Status: Closed

ProT4
Multicentre randomised phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for haematological cancers

ProT4 is a multicentre, randomised phase II trial to evaluate the efficacy of prophylactic transfer of donor CD4 lymphocytes after T-cell depleted reduced intensity allogeneic transplantation for haem [...]

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

R2W
Randomised phase 2 trial in WM - Subcutaneous Bortezomib, Clycophosphamide and Rituximab (BCR versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenstr?m’s macroglobulinaemia (WM): a randomised phase II trial

R2W is a randomised (2:1), non-comparative, multicentre, phase II trial of bortezomib, cyclophosphamide and rituximab (BCR – experimental) versus fludarabine, cyclophosphamide and rituximab (FCR – con [...]

Area: Haematological cancer

Phase: Phase II

Status: Closed

RADAR
A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma

Eligible patients will be randomised to either ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or A2VD (doxorubicin, brentuximab vedotin, vinblastine, dacarbazine).Patients will have a PET-CT [...]

Area: Haematological cancer

Phase: Phase III

Status: Active (recruiting)

RAINBOW
Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström’s macroglobulinaemia

The RAINBOW study is a phase 2-3 trial assessing ‘chemotherapy free’ treatment as primary therapy for Waldenström’s macroglobulinaemia (WM) which can potentially improve response outcome, durability a [...]

Area: Haematological cancer

Phase: Phase II/III

Status: Active (recruiting)

RAPID
A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin’s Disease

A randomised (1:1), multicentre, phase III trial to determine whether patients with clinical stage IA/IIA Hodgkin’s disease who have a negative FDG-PET scan after 3 cycles of ABVD require consolidatio [...]

Area: Haematological cancer

Phase: Phase III

Status: In follow-up (non-recruiting)

RATHL
A randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma

RATHL is a multi-centre randomised trial comparing treatment outcome for patients with advanced Hodgkin lymphoma, using FDG-PET imaging after 2 cycles of ABVD to determine response and subsequent mana [...]

Area: Haematological cancer

Phase: Phase III

Status: In follow-up (non-recruiting)

RATiFY
Response Adapted incorporation of Tislelizumab into the Front-line treatment of older patients with Hodgkin lYmphoma

A phase II, multicentre, non-randomised, open label study.

Area: Haematological cancer

Phase: Phase II

Status: In set-up (funded)

R-CHOP 14 vs 21
A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma.

A multicentre randomised trial comparing R-CHOP 14 given for 6 cycles with R-CHOP 21 given for 8 cycles in patients with newly diagnosed CD20 positive diffuse large B cell lymphoma, bulky stage IA to [...]

Area: Haematological cancer

Phase: Phase III

Status: Closed

R-CODOX-M/IVAC (aka RCM)
R-CODOX-M/IVAC: A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt’s Lymphoma (BL) of International Prognostic Index (IPI) High or High I

Area: Haematological cancer

Phase: Phase II

Status: Closed

ReBeL
ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients >= 18 years with relapsed follicular lymphoma. A HOVON/GLSG/NCRI study

ReBeL is a prospective, randomised, multicentre, international phase II trial (phase I is not being conducted in the UK). ReBeL has two experimental arms; lenalidomide and rituximab versus lenalidomid [...]

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

REMIT
RadiothErapy priMIng for CAR-T

This is an open label, single arm phase IIa study investigating RT as preferred bridging modality prior to Tisagenlecleucel infusion in subjects with relapsed/refractory DLBCL approved to receive CD19 [...]

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

RETRO-CHOP
A retrospective translational study: Characterisation of molecular predictors of outcome in patients with diffuse large B cell lymphoma treated on the R-CHOP14 vs 21 multicentre trial

This is a retrospective study which aims to perform biomarker analyses on archived samples from patients with diffuse large B cell lymphoma (DLBCL) who have been treated on the R-CHOP 14 vs 21 multice [...]

Area: Haematological cancer

Phase: Tissue collection

Status: Active (recruiting)

RIC UCBT
Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning Regimen

RIC-UCBT is a multicentre phase II single-arm trial of reduced-intensity conditioned umbilical cord blood transplantation in patients with haematological diseases.

Area: Haematological cancer

Phase: Phase II

Status: Closed

ToTem
Phase I study of transfer of effector memory T cells (Tem) following allogeneic stem cell transplantation

ToTem is a national phase I trial studying the transfer of effector memory T cells (Tem) in patients eligible for allogeneic stem cell transfer. A Bayesian Time-to-Event Continual Reassessment Method [...]

Area: Haematological cancer

Phase: Phase I

Status: Active (recruiting)

Triangle
Autologous transplantation after a rituximab/ ibrutinib/ Ara-C containing induction in generalized mantle cell lymphoma – a randomized European MCL network trial.

Triangle is a randomized, three-arm, parallel-group, open label international phase III trial.

Area: Haematological cancer

Phase: Phase III

Status: Archived

UKALL14
A randomised trial for adults with newly diagnosed acute lymphoblastic leukaemia

UKALL14 is a Phase III multicentre randomised trial for adults with newly-diagnosed Acute Lymphoblastic Leukaemia (ALL). The main randomisations investigate standard induction chemotherapy with or wit [...]

Area: Haematological cancer

Phase: Phase III

Status: In follow-up (non-recruiting)

UKALL60
A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia

UKALL60+ is a multicentre, non-randomised Phase II trial forolder patients with Acute Lymphoblastic Leukaemia (ALL). There are four treatment pathways based on standard practice here in the UK and in [...]

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

UK-Haplo
UK-Haplo: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies

UK Haplo is a multicentre, non-randomised Phase II trial in patients with haematological malignancies to investigate whether it is possible to carry out haploidentical peripheral blood stem cell trans [...]

Area: Haematological cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

Watch & Wait
An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a)

The Watch and Wait study is a randomised phase III trial to determine whether giving treatment with rituximab to patients with advanced stage asymptomatic follicular lymphoma (grades 1, 2 and 3a) resu [...]

Area: Haematological cancer

Phase: Phase III

Status: In follow-up (non-recruiting)

ZEBRA
Zanubrutinib plus rituximab (Zanu-R) as fixed duration, early intervention versus observation for patients with indolent mantle cell lymphoma: a randomised phase II clinical trial

ZEBRA is a phase II, multicentre, randomised open label study to assess the safety and efficacy of zanubrutinib in combination with rituximab for previously untreated indolent Mantle Cell lymphoma pat [...]

Area: Haematological cancer

Phase: Phase II

Status: Active (recruiting)